HK1210166A1 - Fused tricyclic amide compounds as multiple kinase inhibitors - Google Patents

Fused tricyclic amide compounds as multiple kinase inhibitors

Info

Publication number
HK1210166A1
HK1210166A1 HK15111004.4A HK15111004A HK1210166A1 HK 1210166 A1 HK1210166 A1 HK 1210166A1 HK 15111004 A HK15111004 A HK 15111004A HK 1210166 A1 HK1210166 A1 HK 1210166A1
Authority
HK
Hong Kong
Prior art keywords
kinase inhibitors
amide compounds
fused tricyclic
multiple kinase
tricyclic amide
Prior art date
Application number
HK15111004.4A
Other languages
English (en)
Chinese (zh)
Inventor
Changyou Zhou
Guoliang Zhang
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of HK1210166A1 publication Critical patent/HK1210166A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK15111004.4A 2013-06-28 2015-11-09 Fused tricyclic amide compounds as multiple kinase inhibitors HK1210166A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2013078317 2013-06-28
PCT/CN2014/080986 WO2014206344A1 (en) 2013-06-28 2014-06-27 Fused tricyclic amide compounds as multiple kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1210166A1 true HK1210166A1 (en) 2016-04-15

Family

ID=52141107

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15111004.4A HK1210166A1 (en) 2013-06-28 2015-11-09 Fused tricyclic amide compounds as multiple kinase inhibitors

Country Status (5)

Country Link
US (1) US9670231B2 (de)
EP (1) EP3013797B1 (de)
JP (2) JP6380862B2 (de)
HK (1) HK1210166A1 (de)
WO (1) WO2014206344A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
WO2014007951A2 (en) 2012-06-13 2014-01-09 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
DK2986610T5 (en) 2013-04-19 2018-12-10 Incyte Holdings Corp BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
EP3013797B1 (de) 2013-06-28 2018-01-03 BeiGene, Ltd. Kondensierte tricyclische amidverbindungen als multiple kinaseinhibitoren
ES2686821T3 (es) 2013-06-28 2018-10-22 Beigene, Ltd. Compuestos tricíclicos fusionados de urea como inhibidores de Raf quinasa y/o dímero de Raf quinasa
KR102402244B1 (ko) 2014-05-21 2022-05-26 솔베이 스페셜티 폴리머즈 유에스에이, 엘.엘.씨. 안정화제 화합물
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
NZ773116A (en) 2015-02-20 2024-05-31 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
SG11201805286RA (en) * 2015-12-24 2018-07-30 Kyowa Hakko Kirin Co Ltd α,β-UNSATURATED AMIDE COMPOUND
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
ES2962605T3 (es) 2018-02-26 2024-03-20 Gilead Sciences Inc Compuestos de pirrolizina sustituidos como inhibidores de la replicación del VHB
US11266624B2 (en) * 2018-04-03 2022-03-08 Texas Tech University System CRM1 inhibitors reduce primary and acquired resistance of EGFR inhibitors in lung cancer cells
SG11202010636VA (en) 2018-05-04 2020-11-27 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
BR112020022373A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation sais de um inibidor de fgfr
TWI849043B (zh) * 2019-01-25 2024-07-21 英屬開曼群島商百濟神州有限公司 B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
BR112022007163A2 (pt) 2019-10-14 2022-08-23 Incyte Corp Heterociclos bicíclicos como inibidores de fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
US11407750B2 (en) 2019-12-04 2022-08-09 Incyte Corporation Derivatives of an FGFR inhibitor
WO2021110141A1 (zh) * 2019-12-06 2021-06-10 南京明德新药研发有限公司 Pan-RAF激酶抑制剂的联芳基化合物
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
KR20230151981A (ko) * 2020-12-11 2023-11-02 에라스카, 아이엔씨. 암 치료를 위한 병용 요법
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
EP4352059A1 (de) 2021-06-09 2024-04-17 Incyte Corporation Tricyclische heterocyclen als fgfr-inhibitoren

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100733D0 (sv) 2001-03-05 2001-03-05 Medivir Ab Non-nucleoside reverse transcriptase inhibitors
WO2003068773A1 (en) 2002-02-12 2003-08-21 Glaxo Group Limited Pyrazolopyridine derivatives
EP1534276B1 (de) * 2002-09-05 2008-11-05 Medivir AB Nicht-nucleoside revers-transcriptase inhibitoren
SI1696920T1 (sl) 2003-12-19 2015-02-27 Plexxikon Inc. Spojine in postopki za razvoj modulatorjev ret
US7618964B2 (en) 2004-12-23 2009-11-17 Hoffmann-La Roche Inc. Benzamide derivatives, their manufacture and use as pharmaceutical agents
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
CA2608733A1 (en) 2005-05-17 2007-02-01 Plexxikon, Inc. Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
EP1902056A2 (de) 2005-05-20 2008-03-26 Array Biopharma, Inc. Raf-hemmende verbindungen und anwendungsverfahren dafür
EP3088400A1 (de) 2005-06-22 2016-11-02 Plexxikon Inc. Pyrrolo[2,3-b]pyridin-derivate als proteinkinasehemmer
CN101305010A (zh) 2005-09-01 2008-11-12 阿雷生物药品公司 Raf抑制剂化合物及其用法
WO2007067444A1 (en) * 2005-12-08 2007-06-14 Millennium Pharmaceuticals, Inc. Bicyclic compounds with kinase inhibitory activity
WO2007136573A2 (en) * 2006-05-15 2007-11-29 Merck & Co., Inc. Antidiabetic bicyclic compounds
CA2662031A1 (en) 2006-09-06 2008-03-13 F. Hoffmann-La Roche Ag Heteroaryl derivatives as protein kinase inhibitors
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
MX2010000617A (es) 2007-07-17 2010-05-17 Plexxikon Inc Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
US20100197924A1 (en) 2008-12-22 2010-08-05 Millennium Pharmaceuticals, Inc. Preparation of aminotetralin compounds
KR20120133377A (ko) 2010-01-27 2012-12-10 네르비아노 메디칼 사이언시스 에스.알.엘. 단백질 키나아제 억제제로서 3,4-디아릴피아졸의 설폰아미도 유도체
WO2011097526A1 (en) 2010-02-05 2011-08-11 Irm Llc Compounds and compositions as protein kinase inhibitors
US8865703B2 (en) 2010-03-26 2014-10-21 Boehringer Ingelheim International Gmbh Pyridyltriazoles
WO2012118492A1 (en) 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
EA025597B1 (ru) * 2011-12-31 2017-01-30 Бейджен, Лтд. КОНДЕНСИРОВАННЫЕ ТРИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Raf КИНАЗЫ
ES2686821T3 (es) 2013-06-28 2018-10-22 Beigene, Ltd. Compuestos tricíclicos fusionados de urea como inhibidores de Raf quinasa y/o dímero de Raf quinasa
EP3013797B1 (de) 2013-06-28 2018-01-03 BeiGene, Ltd. Kondensierte tricyclische amidverbindungen als multiple kinaseinhibitoren

Also Published As

Publication number Publication date
US9670231B2 (en) 2017-06-06
JP6380862B2 (ja) 2018-08-29
JP2018184439A (ja) 2018-11-22
US20160159820A1 (en) 2016-06-09
EP3013797A1 (de) 2016-05-04
JP2016523270A (ja) 2016-08-08
EP3013797A4 (de) 2016-12-07
WO2014206344A1 (en) 2014-12-31
EP3013797B1 (de) 2018-01-03

Similar Documents

Publication Publication Date Title
HK1210166A1 (en) Fused tricyclic amide compounds as multiple kinase inhibitors
HUS2200010I1 (hu) Kondenzált heterociklusos vegyületek protein-kináz inhibitorként
HK1253099A1 (zh) 作為激酶抑制劑的雜環酰胺
HK1212692A1 (zh) 作為激酶抑制劑的聯芳基酰胺化合物
HK1220459A1 (zh) 激酶抑制劑
HK1225735A1 (zh) 絲氨酸/蘇氨酸激酶抑制劑
IL244224A0 (en) Pyro- and Thiane-Pyrimide Carboxamide Compounds for Use as Pim Kinase Inhibitors
HK1223877A1 (zh) 絲氨酸/蘇氨酸激酶抑制劑
HK1211578A1 (en) Amidoimidazopyridazines as mknk-1 kinase inhibitors mknk-1
HK1219104A1 (zh) 激酶抑制劑
IL243295A0 (en) Carbazole carboxamide compounds are useful as kinase inhibitors
ZA201604461B (en) Serine/threonine kinase inhibitors
EP2968331A4 (de) Pyrrolopyrimidinverbindungen als kinaseinhibitoren
GB201307155D0 (en) Kinase inhibitors
GB201309603D0 (en) Novel compounds and their use as kinase inhibitors
GB201305741D0 (en) Novel compounds and their use as kinase inhibitors